Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: michael_f_murphy who wrote (336)	2/25/2003 8:48:06 AM
From: nigel bates	Respond to of 1840

That might be good news for the Boehringer Ingelheim / IMGN project ? Message 18113718

To: michael_f_murphy who wrote (336)	3/11/2003 2:53:17 PM
From: tuck	Respond to of 1840

[Breast cancer: CD44+/CD24-] Michael, here's that Clarke abstract: >>Published online before print March 10, 2003 Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0530291100 Cell Biology Prospective identification of tumorigenic breast cancer cells Muhammad Al-Hajj , Max S. Wicha , Adalberto Benito-Hernandez , Sean J. Morrison , and Michael F. Clarke ¶ Departments of *Internal Medicine and Pathology, Comprehensive Cancer Center, Department of Developmental Biology, and Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109 Communicated by Jack E. Dixon, University of Michigan Medical School, Ann Arbor, MI, January 16, 2003 (received for review December 18, 2002) Breast cancer is the most common malignancy in United States women, accounting for >40,000 deaths each year. These breast tumors are comprised of phenotypically diverse populations of breast cancer cells. Using a model in which human breast cancer cells were grown in immunocompromised mice, we found that only a minority of breast cancer cells had the ability to form new tumors. We were able to distinguish the tumorigenic (tumor initiating) from the nontumorigenic cancer cells based on cell surface marker expression. We prospectively identified and isolated the tumorigenic cells as CD44+CD24-/lowLineage- in eight of nine patients. As few as 100 cells with this phenotype were able to form tumors in mice, whereas tens of thousands of cells with alternate phenotypes failed to form tumors. The tumorigenic subpopulation could be serially passaged: each time cells within this population generated new tumors containing additional CD44+CD24-/lowLineage- tumorigenic cells as well as the phenotypically diverse mixed populations of nontumorigenic cells present in the initial tumor. The ability to prospectively identify tumorigenic cancer cells will facilitate the elucidation of pathways that regulate their growth and survival. Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies.<< Cheers, Tuck